Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce vel magna arcu. Vivamus ultricies sed nisl sit amet semper. Mauris lobortis justo ac sagittis congue. Sed eget velit interdum, viverra sem ultrices, luctus felis. Vivamus faucibus purus velit, ac hendrerit eros tempus et. Aenean tempus, odio eget ullamcorper pellentesque, arcu massa varius justo, sit amet pulvinar risus turpis ac metus. Phasellus sed urna ut libero luctus mollis sed at eros.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce vel magna arcu. Vivamus ultricies sed nisl sit amet semper. Mauris lobortis justo ac sagittis congue. Sed eget velit interdum, viverra sem ultrices, luctus felis. Vivamus faucibus purus velit, ac hendrerit eros tempus et. Aenean tempus, odio eget ullamcorper pellentesque, arcu massa varius justo, sit amet pulvinar risus turpis ac metus. Phasellus sed urna ut libero luctus mollis sed at eros.
Chris Muller Ph.D.
Chris is a scientific founder and current Board member of Apic Bio, where he has worked to advance gene therapies for amyotrophic lateral sclerosis and alpha-1 antitrypsin deficiency (AATD), and serves on the scientific advisory board of Gemini Therapeutics, which focuses on multi-modal therapeutic approaches for age-related macular degeneration and other ophthalmologic diseases.
Since receiving his PhD from the University of Florida, Gainesville and completing postdoctoral training at Univ. Mass. Medical School with Dr. Terry Flotte, Chris has had a distinguished academic research career, establishing himself as a thought leader in gene therapy and working on novel vector platforms, nuclease free gene editing approaches, and mechanisms of gene silencing in the CNS, publishing more than 75 papers and holding more than 10 patents. He has worked on translating AAV mediated gene therapies to the clinic in AATD, Huntington’s Disease and ALS. Notably the was the first to describe a regulatory T- cell responses to the AAV capsid in patients, as well as the first to translate AAV mediated RNAi into humans. He also completed a M.Sc. in Clinical Investigations while on the faculty of UMMS.
A sought after speaker at national and international scientific meetings, Chris has been the recipient of many honors and awards for his research, including the Bettina Irvine Family Award for Excellence in Alpha-1 Research in 2018, and the ALS Angel Fund Angel Award in 2016. In 2017, Chris was honored for holding one of the top 12 patents in Massachusetts by the Boston Patent Law Association, for inventing dual function AAV vectors with a silence and replace modality, among many other recognitions of his work.
Frank Alexis Ph.D.
Dr Frank Alexis obtained his Ph.D. in 2005 in Materials Science from the Nanyang technological University (Singapore). His has more than 20 years experience with biomaterials and nanomaterials. His Ph.D. thesis focused on drug release and degradation mechanisms of biodegradable drug eluting stents. As a postdoctoral fellow at the Brigham and Women’s Hospital in the laboratory of Dr Omid Farokhzad and Research Affiliate at the Massachusetts Institute of Technology from 2006 to 2009 in the laboratory of Prof. Robert Langer, he developed multiple polymeric nanoparticle technologies including targeted nanoparticles for cancer therapy, oral drug delivery, and vaccines. I have published 85 manuscripts and reviews, and 7 book chapters. Among these publications, my review published in Molecular Pharmaceutics has been listed as most accessed for the past seven years (more than 2500 citations) and four of my recent research from Clemson University and YachayTech have been highlighted as cover art and frontispiece. His research has been highly cited with more than 9000 citations (Google Scholar). In addition to his publications, he holds 16 intellectual properties, including 9 licensed to industry. He was listed in Nature Biotechnology as Top Translational Junior Faculty in 2013. He mentored more than 150 undergraduate students and graduated five Ph.D. students.
Si Amar Dahoumane Ph.D.
Dr. Si Amar Dahoumane earned his PhD from Paris-Diderot University, France, in 2011. Then he moved to Canada to carry out a post-doctoral fellowship at McMaster University and work in education and research. In January 2016, he joined Yachay Tech as lecturer at the School of Biological Sciences and Engineering; in October 2018, he was promoted as a full professor of biomedical engineering, a career for which he has been actively involved in the teaching of Nanobiotechnology, Biophysics, Biosensors and Drug Delivery Technology.
Research interests of Dr. Dahoumane include the production of polymeric nanoparticles for biomedical applications, development of innovative routes for the synthesis of inorganic nanoparticles, green processes for the fabrication of various nanomaterials in addition to the generation of biomolecules of interests.
Dr. Dahoumane serves as a member of the Graduate Faculty of Lamar University (USA) and of the Editorial Board of Molecules (MDPI).
Lilian Spenser Ph.D.
Short Biocver
- Doctor of Philosophy, PhD. Division of Parasitology, National Institute for Medical Research. (Now Francis Crick Institute, London – U.K.)
- Full Professor, Universidad Simon Bolívar, Department of Cell Biology, Caracas Venezuela. (from 2009- present).
- Principal Professor at Yachay Tech University.
Summary of Interests
- Currently, my research interests are mainly the study of Disciplines: Immunology, Cell Biology, Biomaterials and Parasitology. Sub-discipline: Immuno-Parasitology.
- Lines: Immunology of tropical diseases. Evaluation of experimental drugs and nano-particles. Production of monoclonal antibodies. Cell culture. Design of serological diagnostic tests and vaccines.
Current Research projects
- Current projects: Evaluation of blood parasites in birds of Ecuador.
- Evaluation of new drugs as anti-malaria effect.
- Evaluation of immune response of biomaterials.
Nelson Vispo Ph.D.
Dr. Nelson Vispo obtained his Ph.D. from for his stays at the University of Rome, Tor Vergata, and the University of Havana. Worked for 20 years at the Center for Genetic Engineering and Biotechnology in Havana, doing different postgraduate studies in Germany and Canada. In October 2014, he joined Yachay Tech as a professor in the Faculty of Biological Sciences and Engineering; He is the author of numerous patents, international publications, and books. Dr. Vispo’s research interests include studies of protein interactions using Phage Display Technology and the development of drugs from drug design to clinical trials.Dr. Vispo is the editor-in-chief of the Bionatura Journal and members of different international scientific societies, among which the Humbolt Foundation, European Association of Science Editors (EASE), and the Council of Science Editors (EE. UU.).
